Should a patient receiving ofatumumab who is varicella‑zoster virus (VZV) antibody positive still be given the recombinant zoster vaccine (Shingrix)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, VZV antibody-positive patients on ofatumumab should still receive Shingrix

Having VZV antibodies does not change the recommendation—patients receiving ofatumumab should receive the recombinant zoster vaccine (Shingrix) regardless of their VZV serostatus. The presence of antibodies indicates prior varicella exposure, which actually makes these patients eligible and appropriate candidates for herpes zoster vaccination, as they are at risk for viral reactivation.

Why VZV Seropositivity Supports Vaccination

The recombinant zoster vaccine is specifically designed to prevent herpes zoster (shingles), which results from reactivation of latent VZV—not primary infection. Over 95% of adults aged ≥50 years are VZV seropositive, and this is precisely the population for whom Shingrix is indicated 1. The vaccine works by boosting cell-mediated immunity against VZV glycoprotein E to prevent reactivation from latency in sensory ganglia.

Ofatumumab and Herpes Zoster Risk

Patients receiving ofatumumab (an anti-CD20 monoclonal antibody) face substantially elevated herpes zoster risk due to B-cell depletion and immunosuppression. Multiple myeloma network guidelines specifically recommend recombinant zoster vaccine for patients on immunosuppressive therapies, including anti-CD20 antibodies 2. The NCCN guidelines state that RZV is recommended for adults ≥18 years who are at increased risk for herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy 3.

Vaccination Strategy for Ofatumumab Patients

Administer two doses of Shingrix 1-2 months apart (the accelerated schedule approved for immunocompromised patients), ideally:

  • Before starting ofatumumab if possible, as immune responses are optimal prior to B-cell depletion 4
  • If already on therapy, vaccinate anyway—studies show patients on anti-CD20 therapies can mount T-cell responses to RZV even with impaired humoral immunity 5, 6
  • Time vaccination at least 2 weeks before the next ofatumumab dose when feasible to maximize response 4

Evidence in Immunocompromised Populations

The recombinant zoster vaccine has demonstrated robust efficacy in immunocompromised patients:

  • 80.4% of patients with hematologic malignancies on immunosuppressive therapy mounted vaccine responses 6
  • Protection persisted through 13 months post-vaccination even in heavily immunosuppressed populations 6
  • The vaccine is non-replicating (not live), making it safe in immunocompromised patients 7, 8—unlike the older live-attenuated zoster vaccine which is contraindicated

Safety Considerations

While Shingrix is more reactogenic than placebo (injection-site pain in ~80%, fatigue in ~58%), these reactions are typically mild-to-moderate and transient 9. Serious adverse events occur at similar rates to placebo 6. The FDA label explicitly states the vaccine is indicated for adults ≥18 years who are or will be immunocompromised 9.

Common pitfall: Do not confuse VZV seropositivity with contraindication. The opposite is true—seronegative patients (no prior varicella) would need varicella vaccination first, not zoster vaccination. VZV antibodies confirm prior exposure and latent virus, making herpes zoster prevention relevant.

Bottom line: Proceed with the two-dose Shingrix series regardless of positive VZV antibodies. The seropositivity confirms the patient has latent virus that could reactivate, and ofatumumab significantly increases this risk. The vaccine's safety profile in immunocompromised patients is well-established 3, 10.

Related Questions

Can an adult who received the varicella (chicken‑pox) vaccine but never had natural chicken‑pox safely receive Shingrix (recombinant zoster vaccine) using the standard dosing schedule?
Why is Shingrix (recombinant zoster vaccine) not included in the list of vaccines that can be kept at room temperature for more than four hours?
Can a 67-year-old patient who has recovered from shingles receive the Shingrix (recombinant zoster) vaccine?
For a patient who has had two episodes of herpes zoster, with the most recent episode occurring 4–5 months ago, what are the current recommendations for zoster vaccination?
Does Shingrix (recombinant varicella‑zoster glycoprotein E vaccine) contain any components that are also present in seasonal influenza vaccines or COVID‑19 vaccines, given the patient experienced drug‑induced liver injury after Shingrix and is hesitant to receive another vaccine?
For a patient with newly diagnosed multiple sclerosis who has been on ofatumumab (Kesimpta) for six months, what is the recommended timing for the shingles vaccine and should therapy be paused before or after vaccination?
Can dexamethasone and diclofenac be mixed in a single intramuscular injection for treatment of radicular lower back pain?
Should we implement real‑time telemedical oversight (ReTMO) with structured stroke protocols and mobile stroke treatment units (MSTUs) for all suspected acute stroke patients to reduce door‑to‑CT time and improve neurological outcomes?
What is the generic name of Azilect (rasagiline)?
What is the Fagotti score and how is it used to guide management in patients with peritoneal carcinomatosis?
Do liver disorders cause an increase in serum vitamin B12 levels?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.